MedTrace Logo

Finerenone for Patients With Primary Aldosteronism (FAIRY)

NCT06457074 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2024-08-30

No results posted yet for this study

Summary

Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).

Conditions

  • Primary Aldosteronism

Interventions

DRUG

Finerenone Oral Tablet

Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

DRUG

Spironolactone Oral Tablet

Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

Sponsors & Collaborators

  • The Affiliated Hospital Of Southwest Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Changzhi Medical College

    collaborator OTHER

  • Qifu Li

    lead OTHER

Principal Investigators

  • Shumin Yang · First Affiliated Hospital of Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-04
Primary Completion
2025-06-01
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06457074 on ClinicalTrials.gov